C Doehn1, M Siebels2, T Steiner3. 1. Urologikum Lübeck, Am Kaufhof 2, 23566, Lübeck, Deutschland. doehn@urologikum-luebeck.de. 2. Urologische Gemeinschaftspraxis Pasing, München, Deutschland. 3. Klinik für Urologie, Helios Klinikum Erfurt, Erfurt, Deutschland.
Abstract
BACKGROUND: Renal cell carcinoma is the third most common tumor of the genitourinary system. Small tumors are increasingly treated by nephron-sparing surgery, focal therapy via cryoablation or radiofrequency ablation and also active surveillance. These treatment options are associated with increased follow-up care. OBJECTIVES: What are the current recommendations on follow-up care for different therapeutic approaches in renal cell carcinoma? MATERIALS AND METHODS: We analyzed different biological aspects regarding renal cell carcinoma, diagnostic procedures as well as recommendations of current guidelines (e.g. German S3, EAU AUA). RESULTS: Follow-up of renal cell carcinoma is not well standardized due to the limited amount of data. In general, follow-up should be intensified during the first 3 years following initial therapy as well as in patients with increased risk for tumor recurrence. For risk calculation different prognostic models based on clinical parameters have been published. CONCLUSIONS: Current recommendations on follow-up care in renal cell carcinoma are based on retrospective studies. Future strategies must include markers and be studied in a prospective manner.
BACKGROUND:Renal cell carcinoma is the third most common tumor of the genitourinary system. Small tumors are increasingly treated by nephron-sparing surgery, focal therapy via cryoablation or radiofrequency ablation and also active surveillance. These treatment options are associated with increased follow-up care. OBJECTIVES: What are the current recommendations on follow-up care for different therapeutic approaches in renal cell carcinoma? MATERIALS AND METHODS: We analyzed different biological aspects regarding renal cell carcinoma, diagnostic procedures as well as recommendations of current guidelines (e.g. German S3, EAU AUA). RESULTS: Follow-up of renal cell carcinoma is not well standardized due to the limited amount of data. In general, follow-up should be intensified during the first 3 years following initial therapy as well as in patients with increased risk for tumor recurrence. For risk calculation different prognostic models based on clinical parameters have been published. CONCLUSIONS: Current recommendations on follow-up care in renal cell carcinoma are based on retrospective studies. Future strategies must include markers and be studied in a prospective manner.
Authors: Börje Ljungberg; Laurance Albiges; Yasmin Abu-Ghanem; Karim Bensalah; Saeed Dabestani; Sergio Fernández-Pello; Rachel H Giles; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Teele Kuusk; Thomas B Lam; Lorenzo Marconi; Axel S Merseburger; Thomas Powles; Michael Staehler; Rana Tahbaz; Alessandro Volpe; Axel Bex Journal: Eur Urol Date: 2019-02-23 Impact factor: 20.096
Authors: Maximiliano Sorbellini; Michael W Kattan; Mark E Snyder; Victor Reuter; Robert Motzer; Manlio Goetzl; James McKiernan; Paul Russo Journal: J Urol Date: 2005-01 Impact factor: 7.450
Authors: Saeed Dabestani; Christian Beisland; Grant D Stewart; Karim Bensalah; Eirikur Gudmundsson; Thomas B Lam; William Gietzmann; Paimaun Zakikhani; Lorenzo Marconi; Sergio Fernandéz-Pello; Serenella Monagas; Samuel Paul Williams; Christian Torbrand; Thomas Powles; Erik Van Werkhoven; Richard Meijer; Alessandro Volpe; Michael Staehler; Börje Ljungberg; Axel Bex Journal: Eur Urol Date: 2018-10-11 Impact factor: 20.096
Authors: Andres F Correa; Opeyemi Jegede; Naomi B Haas; Keith T Flaherty; Michael R Pins; Edward M Messing; Judith Manola; Christopher G Wood; Christopher J Kane; Michael A S Jewett; Janice P Dutcher; Robert S DiPaola; Michael A Carducci; Robert G Uzzo Journal: J Clin Oncol Date: 2019-06-19 Impact factor: 44.544
Authors: Sabine Brookman-May; Matthias May; Shahrokh F Shariat; Evanguelos Xylinas; Christian Stief; Richard Zigeuner; Thomas Chromecki; Maximilian Burger; Wolf F Wieland; Luca Cindolo; Luigi Schips; Ottavio De Cobelli; Bernardo Rocco; Cosimo De Nunzio; Bogdan Feciche; Michael Truss; Christian Gilfrich; Sascha Pahernik; Markus Hohenfellner; Stefan Zastrow; Manfred P Wirth; Giacomo Novara; Marco Carini; Andrea Minervini; Claudio Simeone; Alessandro Antonelli; Vincenzo Mirone; Nicola Longo; Alchiede Simonato; Giorgio Carmignani; Vincenzo Ficarra Journal: Eur Urol Date: 2012-06-22 Impact factor: 20.096
Authors: L Cindolo; A de la Taille; G Messina; L Romis; C C Abbou; V Altieri; A Rodriguez; J J Patard Journal: BJU Int Date: 2003-12 Impact factor: 5.588
Authors: Sherri M Donat; Mireya Diaz; Jay Todd Bishoff; Jonathan A Coleman; Philipp Dahm; Ithaar H Derweesh; S Duke Herrell; Susan Hilton; Eric Jonasch; Daniel W Lin; Victor E Reuter; Sam S Chang Journal: J Urol Date: 2013-05-07 Impact factor: 7.450
Authors: Pierre I Karakiewicz; Alberto Briganti; Felix K-H Chun; Quoc-Dien Trinh; Paul Perrotte; Vincenzo Ficarra; Luca Cindolo; Alexandre De la Taille; Jacques Tostain; Peter F A Mulders; Laurent Salomon; Richard Zigeuner; Tommaso Prayer-Galetti; Denis Chautard; Antoine Valeri; Eric Lechevallier; Jean-Luc Descotes; Herve Lang; Arnaud Mejean; Jean-Jacques Patard Journal: J Clin Oncol Date: 2007-04-10 Impact factor: 44.544
Authors: Bradley C Leibovich; Michael L Blute; John C Cheville; Christine M Lohse; Igor Frank; Eugene D Kwon; Amy L Weaver; Alexander S Parker; Horst Zincke Journal: Cancer Date: 2003-04-01 Impact factor: 6.860